Lacutamab is a Monoclonal Antibody owned by Innate Pharma, and is involved in 4 clinical trials, of which 1 was completed, and 3 are ongoing.

Lacutamab (IPH-4102) is a mAb against KIR3DL2, a unique tumor antigen expressed on T cell lymphomas. The therapeutic candidate binds to KIR3DL2 expressing cancer cells and increases recruitment of NK cells thereby depleting tumor cells.

The revenue for Lacutamab is expected to reach a total of $563m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lacutamab NPV Report.

Lacutamab was originated by University of Genoa and is currently owned by Innate Pharma.

Lacutamab Overview

Lacutamab (IPH-4102) is under development for the treatment of relapsed and refractory sezary syndrome (SS),cutaneous T-cell lymphomas such as transformed mycosis fungoides (TMF),and relapsed and refractory including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), follicular T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, adult T-cell leukemia/lymphoma (ATL), hepatosplenic T-cell lymphoma (HSTL), enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and aggressive NK-cell leukemia (ANKL). It was administered intravenously. The drug candidate is a cytotoxic antibody against KIR3DL2-expressing cancers.

Innate Pharma Overview

Innate Pharma is a biotechnology company that develops antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory (r/r) hairy cell leukemia. The company is investigating Lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody for cutaneous T-cell lymphoma (CTCL); Monalizumab, an immune checkpoint inhibitor targeting solid tumors, head and neck cancer, and Avdoralimab antibody against bullous pemphigoid. Innate Pharma is also evaluating IPH5201, IPH5301, IPH6101 and IPH62 antibodies for the treatment of various of tumors. It works in partnership with Sanofi SA, AstraZeneca Plc and other biopharmaceutical companies to develop its products. Innate Pharma is headquartered in Marseille, Provence Alpes Cote d’Azur, France.

The company reported revenues of (Euro) EUR12.1 million for the fiscal year ended December 2021 (FY2021), a decrease of 78.4% over FY2020. The operating loss of the company was EUR47.8 million in FY2021, compared to an operating profit of EUR1.1 million in FY2020. The net loss of the company was EUR52.8 million in FY2021, compared to a net loss of EUR64 million in FY2020.

Quick View – Lacutamab

Report Segments
  • Innovator
Drug Name
  • Lacutamab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.